Beacon Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$2.75M Sell
48,559
-2,652
-5% -$145K 0.43% 80
2016
Q4
$2.99M Sell
51,211
-72,255
-59% -$3.95M 0.49% 72
2016
Q3
$6.66M Sell
123,466
-10,738
-8% -$690K 1.12% 28
2016
Q2
$9.87M Sell
134,204
-3,902
-3% -$276K 1.68% 13
2016
Q1
$8.82M Sell
138,106
-5,283
-4% -$333K 1.53% 16
2015
Q4
$9.86M Sell
143,389
-5,773
-4% -$381K 1.71% 12
2015
Q3
$8.83M Sell
149,162
-20,545
-12% -$1.3M 1.56% 15
2015
Q2
$11.3M Sell
169,707
-7,714
-4% -$508K 1.82% 8
2015
Q1
$11.4M Sell
177,421
-2,793
-2% -$175K 1.74% 8
2014
Q4
$10.6M Buy
180,214
+11,958
+7% +$674K 1.64% 12
2014
Q3
$8.61M Sell
168,256
-8,909
-5% -$445K 1.42% 18
2014
Q2
$8.59M Sell
177,165
-56,533
-24% -$2.79M 1.41% 16
2014
Q1
$12.1M Sell
233,698
-15,177
-6% -$808K 2.08% 5
2013
Q4
$13.2M Sell
248,875
-44,467
-15% -$2.27M 2.27% 5
2013
Q3
$13.6M Buy
293,342
+745
+0.3% +$32.7K 2.51% 4
2013
Q2
$13.1M Buy
+292,597
New +$12.7M 2.49% 4

Other funds holding BMY

Beacon Trust's BMY Position: Q1 2017 in Review

Beacon Trust reduced its Bristol-Myers Squibb (BMY) stake by 5.2% in Q1 2017, selling an estimated $145K and leaving 48,559 shares worth $2.75M. The position accounts for 0.43% of the portfolio, ranked #80.

Beacon Trust first reported a position in BMY in Q2 2013 and has held it in 16 quarters since. The position peaked at $13.6M in Q3 2013. 1,597 funds tracked by Wall St. Rank hold BMY as of Q1 2017.

  • Beacon Trust held 48,559 shares of Bristol-Myers Squibb worth $2.75M as of Q1 2017.
  • Beacon Trust sold 2,652 Bristol-Myers Squibb shares in Q1 2017, an estimated $145K.
  • Bristol-Myers Squibb made up 0.43% of Beacon Trust's portfolio in Q1 2017, its #80 holding.
  • Beacon Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 16 quarters since.
  • Beacon Trust's Bristol-Myers Squibb position peaked at $13.6M in Q3 2013.
  • 1,597 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2017.

Based on Beacon Trust's 13F filing for Q1 2017, filed 9 May 2017.